|
ATG4C expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.62447832963153E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
<1E-12 |
| Normal-vs-Stage2 |
5.89817084062361E-12 |
| Normal-vs-Stage3 |
<1E-12 |
| Normal-vs-Stage4 |
1.62447832963153E-12 |
| Stage1-vs-Stage2 |
7.464600E-01 |
| Stage1-vs-Stage3 |
3.304200E-02 |
| Stage1-vs-Stage4 |
2.179700E-04 |
| Stage2-vs-Stage3 |
2.318400E-01 |
| Stage2-vs-Stage4 |
2.016200E-02 |
| Stage3-vs-Stage4 |
1.348390E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
<1E-12 |
| Normal-vs-AfricanAmerican |
6.89870049974672E-10 |
| Normal-vs-Asian |
1.64057656348859E-12 |
| Caucasian-vs-AfricanAmerican |
7.032400E-01 |
| Caucasian-vs-Asian |
9.517000E-01 |
| AfricanAmerican-vs-Asian |
6.583200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
6.66133814775094E-16 |
| Normal-vs-Female |
1.62447832963153E-12 |
| Male-vs-Female |
8.483400E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.62470037423645E-12 |
| Normal-vs-Age(41-60Yrs) |
1.11022302462516E-16 |
| Normal-vs-Age(61-80Yrs) |
1.62447832963153E-12 |
| Normal-vs-Age(81-100Yrs) |
1.647030E-04 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
7.309800E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
1.719640E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
8.732800E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
3.099400E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
8.018400E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
4.769600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
2.482800E-03 |
| Classical-VS-Follicular |
1.139720E-02 |
| Classical-VS-Other |
9.643000E-01 |
| Classical-VS-Normal |
1.62447832963153E-12 |
| Tall-VS-Follicular |
2.42019999999732E-05 |
| Tall-VS-Other |
3.309800E-01 |
| Tall-VS-Normal |
<1E-12 |
| Follicular-VS-Other |
4.484800E-01 |
| Follicular-VS-Normal |
5.53660000068845E-08 |
| Other-VS-Normal |
2.241400E-04 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
<1E-12 |
| Normal-vs-N1 |
<1E-12 |
| N0-vs-N1 |
3.843600E-04 |
|
|
